From a therapeutic perspective, targeting the molecular components of the “Black” module, such as WNT5A, EPHA2, and EGFR, could offer promising strategies to counteract tumor invasiveness and overcome drug resistance, particularly in Cluster B patients, who may be more responsive to such inhibitors. Here, EPHA2 is linked to neoplasm.